Yanqiao Zhang

机构：Harbin Medical University, Shaanxi Provincial People's Hospital, Third Affiliated Hospital of Harbin Medical University

发表论文 55 篇 · 总被引 2626 次 · h-index 18

代表论文

• Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial (2025 · The Lancet · 被引 127)
• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 88)
• The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update (2024 · 癌症：英文版 · 被引 66)
• APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 (2024 · Hepatology International · 被引 57)
• Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 20)
• Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors (2024 · Chinese Journal of Cancer Research · 被引 18)